kyron.bio

kyron.bio Announces Strategic Partnership with Servier to Advance Precision Glycosylation in Antibody Therapeutics

Innovative glycobiology platform aimed at enhancing the efficacy, safety, and scalability of next-generation antibody therapeutics across multiple disease areas 9 March 2026 -- Paris, France -- kyron.bio, a biotechnology company pioneering precision glycoengineering for antibody therapeutic development, today announced a strategic partnership with Servier, an international pharmaceutical group governed by a Foundation. Under the terms of...
Paris Biotech Santé-Site Cochin 27 rue du Faubourg Saint Jacques 75014 Paris, France